Bionano Genomics, Inc. Q2 2025 Earnings Recap

Bionano's Q2 2025 results reflect strategic progress with a 5% adjusted revenue decline despite a robust 17% year-over-year increase in flowcell sales, driven by routine user engagement.

Key Takeaways

• Total revenue for Q2 2025 was $6.7 million, a 13% decline from Q2 2024, but a 5% decrease when excluding discontinued services.
• Flowcell sales surged 17% year-over-year, indicating strong demand within the routine user base.
• Non-GAAP gross margin improved significantly to 52%, up from 35% in the same quarter last year.
• Operating expenses were reduced by 53% year-over-year, totaling $8.8 million in Q2 2025.
• The installed base of optical genome mapping systems remains stable at 378, with 16 new systems installed in the first half of 2025.